Extrait

The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg administered twice a day orally versus a placebo as a modifying treatment of the disease in patients with the progressive forms of Multiple Sclerosis (MS). The principal outcome is to determine the efficacy, of andrographolide in retarding the progression of brain atrophy in patients with progressive forms of MS.

Critère d'inclusion

• Primary progressive multiple sclerosis ,Multiple Sclerosis, Secondary Progressive

Liens

• nct
• ictrp